Clinical trial
A Phase 3, Multicenter ,Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease
NCT02187003 is registered in ClinicalTrials.gov with Biossil Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicenter ,Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease
- Lead sponsor
- Biossil Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 17, 2015
- Completion date
- June 27, 2019
- Enrollment
- 345 (actual)
- Sites
- 142
Conditions
As the registry lists them; a condition with its own page is linked.